<DOC>
	<DOCNO>NCT00373165</DOCNO>
	<brief_summary>Study Phase : IV Study Type : Open-label , multicenter , randomise clinical trial two arm stratify intensified immunosuppressive regimen patient high risk acute rejection . Study Description : 148 kidney transplant recipient risk CMV disease randomize treated ganciclovir capsule 3 month ( Group A , prophylaxis , N=74 ) receive ganciclovir IV case proven CMV viral load ( Group B , preemptive therapy , N=74 ) . Initially , 2 month follow plan trial . However , study group decide offer longterm follow patient amend protocol , respectively . The aim study identify efficacious way prevent renal transplant recipient CMV disease find , one two strategy may increase graft patient survival . Therefore , wellknown approach CMV prevention compare two study group : Prophylaxis ( Group A ) : Oral primary prophylaxis ganciclovir capsule start directly transplantation perform day 90 . In case CMV infection ( proven CMV viral load ) symptomatic CMV disease , treatment ganciclovir IV initiate . Preemptive Therapy ( Group B ) : No oral primary prophylaxis give . Treatment ganciclovir IV give patient proven CMV viral load ( CMV infection CMV disease ) .</brief_summary>
	<brief_title>Prophylaxis With Ganciclovir Improves Graft Survival Renal Allograft Recipients</brief_title>
	<detailed_description>Disease Background : More 60 % adult people asymptomatically infect cytomegalovirus ( CMV ) . Due immunosuppressive therapy , renal graft recipient risk CMV infection life-threatening disease . CMV cause variety symptom immunocompromised host , include CMV retinitis , pneumonia colitis . After graft , CMV disease commonly occur transplanted organ trigger graft dysfunction acute rejection . Therefore , prophylaxis preemptive therapy use order prevent graft recipient CMV disease . - CMV prophylaxis mean administration antiviral agent patient risk CMV disease , directly transplantation , i.e . 3 month . Prophylaxis particular use patient high risk CMV disease . - CMV preemptive therapy ( target prophylaxis ) mean CMV monitor initiation induction therapy antiviral agent patient proven CMV viral load ( CMV infection ) . This prevent non-infected patient expose antiviral drug related side effect like neutropenia renal toxicity . Preemptive therapy particular use patient low moderate risk CMV disease . Study Description : 148 kidney transplant recipient risk CMV disease randomize treated ganciclovir capsule 3 month ( Group A , prophylaxis , N=74 ) receive ganciclovir IV case proven CMV viral load ( Group B , preemptive therapy , N=74 ) . Initially , 2 month follow plan trial . However , study group decide offer longterm follow patient amend protocol , respectively . The aim study identify efficacious way prevent renal transplant recipient CMV disease find , one two strategy may increase graft patient survival . Therefore , wellknown approach CMV prevention compare two study group : Prophylaxis ( Group A ) : Oral primary prophylaxis ganciclovir capsule start directly transplantation perform day 90 . In case CMV infection ( proven CMV viral load ) symptomatic CMV disease , treatment ganciclovir IV initiate . Preemptive Therapy ( Group B ) : No oral primary prophylaxis give . Treatment ganciclovir IV give patient proven CMV viral load ( CMV infection CMV disease ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Herpesviridae Infections</mesh_term>
	<mesh_term>DNA Virus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Kidney transplant recipient live postmortal donation CMV seropositive donor recipient kidney transplant : D+/R , D+/R+ D/R+ Laboratory parameter : 50.000/ml thrombocyte and/or 1000/ml neutrophil Immunosuppression include MMF Main Woman pregnant , breastfeed use unreliable birth control method Forbidden concomitant medication 12 month observation period study : Virustatic drug , active CMV : Foscarnet , Cidofovir ( HPMPC ) , Acyclovir , Valaciclovir , Famciclovir/Penciclovir , Lobucavir , Antisense compound Antimetabolites : Fluorouracil , Mercaptopurine , Methotrexate , Thioguanine , Hydroxurea Alkylating substance : Busulfan , Carmustine , Chlorambucil , Cisplatin , Cyclophosphamide , Dacarbazine ( DTIC ) , Lomustine , Mechlormethamine , Melphalan , Streptozotocin , Tiothepa , Uracil mustard anti CMV immunoglobulin ( except case sign CMV infection ) anti CMV hyperimmunoglobulins immunoglobulin Known hypersensitivity ganciclovir Patients active CMV infection positive viraemia randomization Severe gastrointestinal disease may interfere oral resorption ganciclovir Conversion immunosuppression ( Replacement MMF ) Participation another clinical drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>CMV</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Preemptive Therapy</keyword>
	<keyword>Graft Survival</keyword>
	<keyword>Proteomics</keyword>
</DOC>